AXL is a novel ERK5/KLF4 target in MEK inhibitor-treated melanoma
RAS/RAF/MEK/ERK1/2 mitogen-activated protein kinase (MAPK) pathway-based treatments, typically combination therapies with inhibitors for oncogenic BRAF V600 (BRAFi) and MEK1/2 (MEKi), are important treatment alternatives to immunotherapy in advanced BRAF-mutated melanoma. However, their benefit is l...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2026-06-01
|
| Col·lecció: | Neoplasia: An International Journal for Oncology Research |
| Matèries: | |
| Accés en línia: | http://www.sciencedirect.com/science/article/pii/S1476558626000308 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|